Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1963 | 0.85 | ALDH1A1 (0.50) | MEN1KMT2AALDH1A1TSHRPKM | |
| SCHEMBL7722774 | 0.82 | MEN1 (0.52) | MEN1KMT2AALDH1A1TSHRPKM | |
| SCHEMBL8397276 | 0.81 | ALDH1A1 (0.44) | ALDH1A1TSHRLMNA | |
| SCHEMBL8399193 | 0.80 | ALDH1A1 (0.37) | MEN1KMT2AALDH1A1TSHRPKM | |
| SCHEMBL14016347 | 0.80 | MEN1 (0.46) | MEN1KMT2AALDH1A1TSHRPKM | |
| SCHEMBL7515108 | 0.79 | MEN1 (0.44) | MEN1KMT2AALDH1A1TSHRPKM | |
| SCHEMBL2410161 | 0.79 | MMP8 (0.49) | MEN1KMT2AALDH1A1TSHRPKM | |
| SCHEMBL7709450 | 0.79 | MEN1 (0.49) | MEN1KMT2AALDH1A1TSHRPKM | |
| SCHEMBL18290151 | 0.79 | MEN1 (0.68) | MEN1KMT2AALDH1A1TSHRPKM | |
| SCHEMBL1026522 | 0.79 | MEN1 (0.44) | MEN1KMT2AALDH1A1TSHRPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5932747-A | Method for preparing 1,3-dioxane compounds | HUELS AKTIENGESELLSCHAFT (DE) | 1999-08-03 | — | — | US | claimed |
| US-5902896-A | Process for preparing bis (hydroxymethyl) compounds | HUELS AKTIENGESELLSCHAFT (DE) | 1999-05-11 | — | — | US | claimed |
| US-20240140957-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2024-05-02 | — | — | US | disclosed |
| WO-2022148422-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2022-07-14 | — | — | WO | disclosed |
| EP-2276772-B1 | BORON OR ALUMINUM COMPLEXES | CENTRE NAT RECH SCIENT (FR) | 2014-08-20 | — | — | EP | disclosed |
| US-8563761-B2 | Boron or aluminum complexes | CENTRE NATIONAL DE LA RECHERCHE (FR) | 2013-10-22 | — | — | US | disclosed |
| US-20110171112-A1 | BORON OR ALUMINUM COMPLEXES | UNIVERSITE DE PICARDIE JULES VERNE (FR) | 2011-07-14 | — | — | US | disclosed |
| CN-102060732-A | 5-amino-4-hydroxy-N-aryl azelamide derivatives as well as preparation methods and medical applications thereof | JIANGSU HENGRUI MEDICINE CO | 2011-05-18 | — | — | CN | disclosed |
| WO-2009122044-A2 | BORON OR ALUMINUM COMPLEXES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-10-08 | — | — | WO | disclosed |
| US-5932747-A | Method for preparing 1,3-dioxane compounds | HUELS AKTIENGESELLSCHAFT (DE) | 1999-08-03 | — | — | US | disclosed |
| US-5902896-A | Process for preparing bis (hydroxymethyl) compounds | HUELS AKTIENGESELLSCHAFT (DE) | 1999-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140957-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | KRAS, NRAS, G3BP1 | MEN1 130/4885KMT2A 1301/4885ALDH1A1 3389/4885 |
| US-20110171112-A1 | BORON OR ALUMINUM COMPLEXES | AFF4, AFF2, AFF1 | MEN1 3452/4885KMT2A 3346/4885ALDH1A1 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.